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ABSTRACT:
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma 
cells (PCs) in the bone marrow (BM). MM is viewed as a clonal disorder due to lack 
of verified intraclonal sequence diversity in the immunoglobulin heavy chain variable 
region gene (IGHV). However, this conclusion is based on analysis of a very limited 
number of IGHV subclones and the methodology employed did not permit simultaneous 
analysis of the IGHV repertoire of non-malignant PCs in the same samples. Here we 
generated genomic DNA and cDNA libraries from purified MM BMPCs and performed 
massively parallel pyrosequencing to determine the frequency of cells expressing 
identical IGHV sequences. This method provided an unprecedented opportunity to 
interrogate the presence of clonally related MM cells and evaluate the IGHV repertoire 
of non-MM PCs. Within the MM sample, 37 IGHV genes were expressed, with 98.9% 
of all immunoglobulin sequences using the same IGHV gene as the MM clone and 
83.0% exhibiting exact nucleotide sequence identity in the IGHV and heavy chain 
complementarity determining region 3 (HCDR3). Of interest, we observed in both 
genomic DNA and cDNA libraries 48 sets of identical sequences with single point 
mutations in the MM clonal IGHV or HCDR3 regions. These nucleotide changes were 
suggestive of putative subclones and therefore were subjected to detailed analysis to 
interpret: 1) their legitimacy as true subclones; and 2) their significance in the context 
of MM. Finally, we report for the first time the IGHV repertoire of normal human 
BMPCs and our data demonstrate the extent of IGHV repertoire diversity as well as 
the frequency of clonally-related normal BMPCs. This study demonstrates the power 
and potential weaknesses of in-depth sequencing as a tool to thoroughly investigate 
the phylogeny of malignant PCs in MM and the IGHV repertoire of normal BMPCs.
INTRODUCTION
Multiple myeloma (MM) is a devastating and 
incurable plasma cell (PC) malignancy that has a median 
survival of 3-4 years following diagnosis and is the second 
most common hematologic malignancy in the United 
States [1, 2]. To improve overall patient outcomes, greater 
insight into disease etiology and progression is needed. 
Like normal B cells and PCs, the most discriminating 
molecular feature of MM cells is the immunoglobulin 
(Ig)  molecule. The  unique  Ig  molecular  fingerprint  is 
determined initially during B cell development when 
the Ig heavy chain variable region gene (IGHV) and 
the Ig light chain variable region gene (IGLV) undergo Oncotarget 2012; 3:  502-513 503 www.impactjournals.com/oncotarget
precise rearrangements. The diversity of the Ig molecular 
fingerprint can be further increased in B lineage cells 
that acquire Ig somatic hypermutations (SHM) during 
germinal center (GC) reactions. Memory B cells, which 
may undergo multiple GC expansions, often display 
particularly unique IGHV and IGLV sequences. The 
IGHV/IGLV sequences, therefore, serve as unparalleled 
identifiers of a given B cell or MM cell clone. 
Within Ig molecules, the complementarity 
determining regions (CDRs) acquire the most SHM and 
thus diversity. The heavy chain CDR3 (HCDR3) serves 
as a unique clonal B cell marker because of a number of 
distinguishing features. Thus, the nucleotide and amino 
acid sequence of the HCDR3 are influenced by: 1) specific 
Ig heavy chain D (IGHD) and J region gene (IGHJ) 
usage; 2) junctional diversity introduced by IGHV-D-J 
rearrangement; 3) the precise IGHD gene reading frame; 
4) addition of non-templated (N) and palindromic (P) 
nucleotides during B cell development; and 5) possible 
SHMs introduced following antigenic stimulation [3-9].
B cell malignancies exist at all stages of B cell 
development and differentiation. Elucidation of the 
molecular characteristics of rearranged IGHV genes and 
the HCDR3 region in particular may offer insight into 
the etiology of B cell malignancies as well as the history 
of malignant B lineage cells, including ongoing genetic 
evolution. For example, B cell malignancies exhibiting 
extensive IGHV intraclonal heterogeneity likely reflect 
transformation of B cells at the GC stage of differentiation 
that retain the ability to undergo SHM whereas those 
with homogeneous IGHV sequences may indicate post-
GC malignant cells that can no longer activate the SHM 
process. Similarly, malignancies with limited intratumor 
IGHV heterogeneity may suggest ongoing genetic 
evolution resulting from multiple transits through GCs or 
non-conventional SHM occurring outside of GCs [10-12].
Thus, molecular IGHV analysis has been an area 
of intense study in B cell malignancies, most notably in 
chronic lymphocytic leukemia where there is a distinct 
bias of IGHV gene usage and the degree of SHM 
correlates with disease prognosis [13-15]. In contrast, less 
effort has been focused on analysis of MM Ig sequences 
[16-22]. Of relevance to this study, others have used IGHV 
sequence analysis to better understand the relationship 
between MM and its known premalignant condition 
monoclonal gammopathy of undetermined significance 
(MGUS) [23, 24] and have shown that while there is 
evidence for intraclonal heterogeneity in MGUS, MM 
PCs are homogeneous [17, 25-27]. This observation is 
compatible with the notion that disease progression to 
MM requires additional genetic changes that may only 
be gained by one of the “sister” clones initially generated 
during the GC response that gave rise to the abnormally 
sized PC expansion underlying the development of 
MGUS. However, these studies were carried out on a 
limited number of subclones for each patient leaving open 
the possibility that MM patients may harbor rare, but 
clonally related PCs potentially resulting from ongoing 
low level clonal evolution. Indeed, tumor heterogeneity 
is a common characteristic of cancer [28] and may reflect 
Figure 1: Ig clone size comparison of DNA versus cDNA as defined by unique HCDR3s. The clone sizes based on unique 
HCDR3 are represented for (A) normal BMPCs and (B) normal residual non-tumor MM PCs after 454 GS-FLX sequencing. Open squares 
(□) represent cDNA and closed circles (•) represent DNA as the starting template. Only clones of size 1-15 sequences are shown.Oncotarget 2012; 3:  502-513 504 www.impactjournals.com/oncotarget
external influences or disordered regulatory mechanisms 
within the neoplastic cells. Furthermore, subtle genetic 
diversity within a clone may suggest a “branching” 
ancestral relationship [29] rather than the essentially linear 
concept of clonal evolution of tumor cells [30].
The advent of massively parallel sequencing has 
permitted extensive analysis of intraclonal heterogeneity 
especially as it relates to IGHV and T cell receptor 
sequences in both normal and malignant B and T cells 
[31-41]. To our knowledge, comprehensive sequencing 
methodologies have not yet been used to study MM. In 
this study, we exploited the power of massively parallel 
sequencing to better understand the phylogeny and 
potential for intraclonal heterogeneity of malignant PCs 
in MM as well as the effects of clonal expansion on 
the remaining non-malignant PC IGHV repertoire. For 
comparison purposes, we also analyzed normal bone 
marrow resident PCs (BMPCs). Lastly, we studied both 
genomic DNA and cDNA to determine which starting 
template better estimates the overall IGHV repertoire 
using deep sequencing methodologies.
RESULTS
Evaluation of clonal MM cells by conventional 
fluorescent sequencing
By direct sequencing and manual subcloning prior to 
454 GS-FLX sequencing, the MM patient sample studied 
in this report was determined by the ImMunoGeneTics 
Information System (IMGT/V-Quest) software to express 
the IGHV3-74 gene with 18 somatic mutations (7.5%) as 
compared to the germline (GL) sequence. Furthermore, 
the IGHD2-2*01 (reading frame 2) and IGHJ4*02 genes 
were used with 11 N nucleotides but no P nucleotides in 
the HCDR3. 
Pyrosequencing using cDNA versus genomic DNA
The IGHV repertoire of the MM patient PCs and 
control BMPCs was analyzed in detail using massively 
parallel sequencing. It is known that PCs express high 
levels of Ig mRNA transcripts and the expression levels of 
Ig mRNA between individual PCs may vary significantly. 
Because this variance could lead to potential artifactual 
skewing of the IGHV repertoire, we compared the 
repertoire  of  IGHV  sequences  amplified  from  cDNA 
versus genomic DNA. Although the analysis of genomic 
DNA would overcome the expression bias of Ig genes 
in cDNA samples, it has the limitation of also capturing 
the non-productively rearranged IGHV sequences. In 
the context of MM, we found that the non-productively 
rearranged IGHV sequences were highly homologous to 
the dominant MM clone but suffered from insertions of 
nucleotides in homopolymer regions or had incomplete 
HCDR3s. After following the methodology which 
eliminated these sequences and others from further 
analysis, we obtained 30,426 and 24,717 IGHV sequences 
in the MM DNA and cDNA cohorts, respectively; whereas 
in the BMPC sample there were 26,559 DNA and 36,150 
Figure 2:  Algorithm for analyzing IGHV sequences (seqs) obtained from MM DNA sample. After filtering the data, the 
remaining productive sequences were categorized by IGHV gene usage and those with the MM clone IGHV3-74 gene were studied in detail 
looking for putative subclones.Oncotarget 2012; 3:  502-513 505 www.impactjournals.com/oncotarget
cDNA sequences (Table S1). IGHV sequences were 
then grouped into clones as defined by identical HCDR3 
amino acid sequences and sorted on the basis of clone 
size. Figure 1 compares the number of unique HCDR3 
sequences observed in normal BMPCs (Panel A) and 
normal residual non-tumor PCs in the MM patient (Panel 
B) when the starting template was cDNA or DNA. Only 
those HCDR3s with clone sizes ranging from 1-15 are 
shown. Figure 1A and Table S2 clearly demonstrate that 
there was a 4.7 fold increase in the number of HCDR3s 
represented by a single sequence in the DNA as compared 
to the cDNA using the BMPC samples. These data validate 
our hypothesis that a better estimate of Ig repertoire is 
achieved using genomic DNA in this type of analysis. Of 
note, the differences between cDNA and DNA were not 
as clearly defined in the MM PC sample most likely due 
to the extreme expansion of the malignant clone, which 
significantly  decreased  the  overall  number  of  IGHV 
sequence reads from non-tumor PCs.
In-depth IGHV analysis of PCs isolated from a 
MM patient
Detailed analysis was then done on the sequences 
generated from the MM patient. Both the DNA and 
cDNA cohorts were analyzed in a parallel manner with 
Figure 2 detailing our data filtering process when DNA 
was the starting template. As expected, the majority of 
productively rearranged sequences in both the DNA and 
cDNA libraries used the IGHV3-74 gene (30,091/30,426 
productive Ig sequences or 98.9% in DNA; 23,790/24,717 
productive Ig sequences or 96.2% in cDNA). The 
IGHV3-74 sequences were then grouped on the basis of 
HCDR3 amino acid sequence. The largest clonal amino 
acid HCDR3 sequence was VREDLSTSTWGFDY and 
29,229 sequences were found using IGHV3-74 with this 
precise HCDR3 in the DNA cohort and 23,125 in the 
cDNA cohort. Within the DNA group, 25,254 sequences 
were identical in nucleotide sequences of the HCDR3 
and IGHV regions (83% of the productive Ig sequences) 
and 18,889 were identical in the cDNA group (81.6% 
of the productive Ig sequences). Based on our findings 
Figure 3: Sequence alignment of MM subclones using IGHV3-74 and the dominant clone HCDR3. The dominant MM 
clone (Dom) and the 9 largest representative subclone sequences with the dominant HCDR3 using the IGHV3-74 gene when DNA is 
the starting template are shown. Dashes indicate sequence homology with the IGHV3-74 GL sequence and nucleotide changes from the 
dominant clone are circled. Sequence numbers with an * indicate that the nucleotide deviations from the dominant clone reflect reversions 
back to GL. Values in parentheses represent the number of identical sequences found in cDNA.Oncotarget 2012; 3:  502-513 506 www.impactjournals.com/oncotarget
that a more extensive IGHV repertoire emerged when 
the starting material was DNA, further analysis was 
focused on the remaining 3,975 out of 29,229 sequences 
in the DNA cohort that were highly likely to be clonally 
related to the dominant clone. To assess whether these 
sequences may represent MM subclones, we followed our 
algorithm to eliminate sequences with pyrosequencing 
errors whereby sequences with any differences from the 
dominant IGHV3-74 clone in or near homopolymers were 
excluded. Sets of identical sequences with sizes less than 
10 (in both the DNA and cDNA samples) or consisting of 
sequences in only one orientation were also eliminated. 
All  remaining  sets  of  sequences  had  a  verified  Phred 
quality score greater than 35 including any deviations 
from the dominant clone, thereby significantly exceeding 
our threshold of 20. After applying this algorithm, 44 
putative subclones (1207 sequences) were identified that 
displayed the dominant HCDR3 but with single nucleotide 
deviations in the IGHV region distinguishing them from 
the dominant clone (Figure 2). The number of sequences 
in each subclone varied from 13-56 in DNA and the 9 
largest of these subclones are shown in Figure 3. As 
required by our algorithm, thorough analysis of the cDNA 
IGHV sequence cohort confirmed the presence of each of 
these subclones with at least 10 sequences. Of note, there 
were 2 subclones (#60 and #69) where the single deviation 
was not a result of an additional mutation but reflected 
the original GL sequence of IGHV3-74 at that particular 
nucleotide (Figure 3). Finally, there were 862 IGHV3-
74 sequences that did not express an HCDR3 identical 
to the dominant MM clone. Using the same algorithm to 
identify subclones within these sequences, we discovered 
4 additional MM-related subclones. These subclones 
(117 sequences) displayed IGHV regions identical to the 
dominant clone but HCDR3 regions that differed by a 
single nucleotide change resulting in an amino acid change 
in the HCDR3 (Figure 4). 
We next focused on the small subset of sequences 
with IGHV designations other than IGHV3-74 (n=335; 
Figure 2). This group consisted of 36 other IGHV genes 
with a range of 1-20 unique HCDR3s in each IGHV gene 
(187 unique HCDR3s total; Figure S1; Table S3). Detailed 
analysis did not uncover any evidence of subclones within 
this group with the majority of the distinctive HCDR3s 
being represented by a single sequence. Of interest, we 
observed sequences that unexpectedly displayed an 
HCDR3 nucleotide and amino acid sequence that was 
identical to the dominant clone. These clones instead 
differed  sufficiently  within  the  IGHV  region  to  be 
classified by IMGT/V-Quest as a different IGHV gene 
(IGHV3-23, 3-48, 3-30, 3-33 and 3-7). Despite being 
found in the cDNA as well, these sequences did not meet 
our criteria for subclone designation and most likely 
represent PCR recombination events (hybrids) resulting 
from amplification of multiple but similar IGHV genes 
[42].
Figure 4:  MM subclones using IGHV3-74 with non-synonymous HCDR3s. Representative subclones with the identical IGHV 
gene as the dominant clone (Dom) but with HCDR3s that varied by 1 amino acid from the dominant sequence when DNA is the starting 
template are shown. Dashed lines indicate sequence homology with the IGHV3-74 GL sequence. Nucleotide deviations from the dominant 
clone are shown and amino acid changes are circled. Values in parentheses represent the number of identical sequences found in cDNA.Oncotarget 2012; 3:  502-513 507 www.impactjournals.com/oncotarget
In-depth IGHV analysis of BMPCs
In another set of analyses, we studied in detail the 
IGHV usage of normal BMPCs using genomic DNA as 
the starting template. We also analyzed each IGHV gene 
for numbers of unique HCDR3 sequences (Figure 5).The 
IGHV repertoire pattern is more diverse than that of the 
presumably normal PCs present in the MM sample with 54 
IGHV genes being represented as compared to 36. Of note, 
all 7 IGHV families are represented in both repertoires 
from the genomic DNA templates. Given that the IGHV6 
and 7 families have few members, it is remarkable that 
we were able to detect these genes and is proof that our 
method of amplification captures all IGHV genes. 
Using the same methodology described for the MM 
cohort we interrogated the normal BMPC IGHV sequence 
set for evidence of clonally related sequences and indeed, 
we found such sequences within the normal BMPCs. 
The largest clone utilized the IGHV3-7 gene with an 
HCDR3 amino acid sequence of ARDGYATGSHDY and 
included 102 identical sequences by both amino acid and 
nucleotide sequences with 5 N and P nucleotides in the 
HCDR3. We also observed two related sets of sequences, 
which consisted of 18 and 5 sequences that had the same 
mutation pattern and HCDR3 as the dominant sequence 
but differed in the IGHV region by 8 and 4 IGHV gene 
mutations, respectively (Figure 6). However, only set #2 
met our criteria for verification (at least 10 sequences 
in both the DNA and cDNA cohort) and was therefore 
considered a subclone. Similar to what was observed in the 
MM patient, some of the nucleotide deviations between 
the subclones and the dominant clone were nucleotides 
that did not appear to mutate from the GL sequence. 
Characterization of somatic mutations in MM 
and BMPC clones and subclones
We observed that each of the putative MM subclones 
displayed only single nucleotide substitutions from 
the dominant clone whereas clonally related BMPC 
sequences differed to an expected greater degree from 
each other. We therefore considered the possibility that 
some of the distinguishing nucleotide substitutions in 
the putative MM subclones instead resulted from Taq 
polymerase errors. To provide a baseline comparison for 
our analysis, we first determined the type of nucleotide 
substitutions exhibited by the dominant IGHV3-74 MM 
clone and the largest IGHV3-7 BMPC clone. We also 
carried out a similar analysis on at least 10 other (non-
dominant) IGHV sequences from both the BMPC and MM 
sequence data sets as well as other MM patient samples 
previously subjected to Sanger sequencing from our tissue 
bank but not part of this detailed pyrosequencing study 
(Tschumper and Jelinek, unpublished data). Because a G 
to A change on one strand cannot be distinguished from 
Figure 5: Number of unique HCDR3s and frequency of specific IGHV gene usage in normal BMPCs. The sequences 
shown here represented 54 IGHV genes.Oncotarget 2012; 3:  502-513 508 www.impactjournals.com/oncotarget
a C to T occurring on the complementary DNA strand, 
we grouped the 12 possible nucleotide substitutions into 
6 categories [43]. Thus, for each sequence analyzed, 
the 12 possible nucleotide substitutions were counted, 
grouped into 6 complementary categories and represented 
as the percent of total mutations for that sequence. When 
the average of percent mutations in the non-dominant 
BMPC and MM sequences are compared to the average 
percent mutations in the dominant BMPC and MM 
clonal sequences (and their respective subclones), there 
is evidence of bias towards transitions over transversions 
(Figure 7A). We next analyzed the type of nucleotide 
substitution displayed by each of the 44 putative MM 
subclones with nucleotide substitutions within the IGHV 
gene. As may be seen in Figure 7B, there was a notable 
overrepresentation of the transitions A-G/T-C in the 
putative MM subclones. Because it is known that Taq 
substitutions at A or T nucleotides are much more frequent 
than at G or C nucleotides [43] these results support a 
cautious interpretation of the significance of these MM 
subclones. 
DISCUSSION 
In this study, we used massively parallel sequencing 
to investigate Ig repertoire profiles within BMPCs from a 
MM patient and from a control patient. Previous studies 
investigating MM IGHV sequences using labor intensive 
techniques concluded that MM cells do not display 
intraclonal IGHV sequence diversity. However, analysis 
was restricted to a small number of subclones (n=3-100, 
based on the specific study) [16, 17, 25-27] and these 
investigators did not definitively identify subclones of the 
dominant clone based on exact identity of the HCDR3. 
By contrast, our use of the Roche 454 GS-FLX Titanium 
chemistry allowed us to analyze approximately 30,000 
Ig sequences increasing the likelihood of detecting rare 
subclones while also providing details regarding the Ig 
repertoire of BM resident non-malignant PCs in a MM 
patient. For comparison purposes, we also analyzed 
the Ig repertoire of normal BMPCs. Data sets of this 
magnitude pose analytic challenges, however, through 
use of previously published methodologies [31, 37] and 
development of our own algorithms, we were able to 
categorize sequences based on HCDR3 identity and IGHV 
gene usage allowing us to identify clonal sequences and 
putative subclones in both the MM and normal BMPC 
samples. 
An initial global analysis verified that the genomic 
DNA samples yielded a more robust overall repertoire 
than did the cDNA samples on the basis of quantitating 
unique HCDR3s (Figure 1). Of the approximately 60 
known IGHV genes in the IMGT/V-Quest reference 
sets (including functional genes and pseudogenes), 54 
genes were identified in the BMPC DNA sample (Figure 
5). Regarding similar analysis of non-tumor PCs in 
the MM sample, we did not identify a large number of 
non-IGHV3-74 non-productive clonal sequences. This 
observation suggests that the myeloma cells from this 
patient most likely express the second Ig heavy chain allele 
in a germline configuration. Despite the relatively low 
numbers of non-clonally related sequences available for 
analysis, it is striking that the few normal PCs coexisting 
with MM PCs remain quite diverse, i.e., 37 IGHV genes 
were represented in this data set. These results suggest 
that the MM clone is indiscriminate in suppressing the 
appearance of normal PCs. Although the IGHV gene 
usage appears to be less diverse than in a normal patient, 
our study design leaves open the possibility that with a 
larger sampling of normal BMPCs within a MM patient, 
we would have observed a higher level of diversity. 
The primary advantage of our study design was our 
ability to rigorously assess the existence of PCs clonally 
related to the predominant MM clone. This is the largest 
reported dataset demonstrating that the vast majority of the 
malignant PCs in a MM patient exhibit an identical IGHV 
Figure 6: Normal BMPC clones with identical HCDR3s. The largest clone, which used the IGHV3-7 gene (Dom), is shown here 
with putative subclones. Dashes indicate sequence homology with the IGHV3-7 GL sequence and nucleotide changes from the dominant 
clone are circled. Sequence numbers with an asterisk indicate that some of  the nucleotide deviations from the dominant clone reflect 
reversions back to GL. Values in parentheses represent the number of identical sequences found in cDNA. Oncotarget 2012; 3:  502-513 509 www.impactjournals.com/oncotarget
gene sequence and is consistent with the conclusions 
reached by other investigators following analysis of much 
smaller sequence cohorts [16, 17, 25-27]. This observation 
is also consistent with the idea that MM is a post-GC 
malignancy that can no longer undergo SHM. As a result 
of the depth of our sequence analysis, however, we also 
uncovered related sequences that were distinguished by a 
single nucleotide substitution whereas similar analysis of 
the clonally related normal BMPC sequences displayed 
multiple nucleotide substitutions. If these single nucleotide 
changes are genuine, it becomes unlikely that the MM-
related subclones arose from the germinal center SHM 
process. Rather, the nucleotide deviations in MM may 
simply represent random somatic mutations occurring 
genome-wide in the tumor cell independent of the GC 
reaction, which deep sequencing allowed us to detect 
(Figure 3). Indeed, MM is believed to be a disease where 
considerable genetic evolution occurs. Whole genome 
sequencing of MM patients revealed unexpected somatic 
mutations across the MM genome as compared to normal 
DNA [44] and we have recently published evidence for 
ongoing double strand DNA breaks in primary MM cells 
[45].
However, it is also possible that some or all of the 
MM-related subclones instead reflect artifacts known to 
be problematic with this methodology. One type of artifact 
is insertions or deletions of the same nucleotide within 
homopolymer regions. By our algorithm, sequences with 
apparent insertions or deletions of the same nucleotide 
within homopolymers (defined as tracts of 4 or more 
of the same nucleotide) or substitutions of nucleotides 
within 2 base pairs of homopolymers were eliminated 
from consideration. These types of sequencing errors also 
may result in a low Phred score. Therefore by requiring a 
Phred score greater than 20, we eliminated errors due to 
homopolymers and other potential sequencing errors. We 
further required that a potential clonally-related sequence 
could only be designated as such if the precise sequence 
could be found a minimum of 10 times in the libraries 
generated from both cDNA and genomic DNA. Sequences 
meeting these criteria could be subdivided into 44 MM-
related subclones, with each putative subclone exhibiting 
an identical HCDR3 region (VREDLSTSTWGFDY) 
and an IGHV3-74 gene with the same mutations as the 
dominant MM clone but with additional subclone-specific 
single point mutations in each sequence. An additional 4 
putative subclones were discovered that expressed IGHV 
regions identical to the dominant clone but varied by a 
single nucleotide in the HDCR3 thus altering the HCDR3 
amino acid sequence. 
The second type of artifact associated with this 
methodology is Taq  polymerase mediated nucleotide 
substitutions which involve errors at A or T nucleotides 
at a much greater rate than G or C nucleotides [43]. 
Because of this bias, we characterized the precise type 
of nucleotide substitution exhibited by each of the 44 
putative MM subclones which expressed single nucleotide 
variances within the IGHV gene. Whereas normal BMPC 
sequences and MM clonal sequences obtained from a 
variety of patients contained nucleotide substitutions 
in all complementary categories, the single nucleotide 
deviations from the dominant clone in the putative 
subclones show a strong bias for G-A/C-T and A-G/T-C 
nucleotide substitutions (Figure 7B). Thus, almost 90% 
of the nucleotide changes were A-G or T-C substitutions, 
thereby calling into question whether all 44 subclones are 
bona fide subclones or whether some or all of them are 
artifacts resulting from Taq polymerase errors [31, 43, 
46]. It should be noted that transition mutations are known 
to occur more frequently in general than transversion 
mutations due to nucleotide molecular structure [47] and 
we indeed observed this in our analysis of the somatic 
mutations displayed by normal BMPCs and MM samples 
(Figure 7A). Of interest, two previous studies of MM Ig 
clonality on a much smaller scale observed changes that 
were also mainly transitions of A-G and T-C and this 
Figure 7: Characterization of mutations in BMPC and MM sequences. For each sequence analyzed, nucleotide substitutions 
were counted, grouped into 6 complementary categories and represented as the percent of total mutations for that sequence. Groups of 
specific sequences were averaged and plotted. (A) The average expression of mutations in non-dominant (Non-Dom) BMPC sequences 
(n=10) and Non-Dom MM sequences (n=18; 8 from this pyrosequencing study and 10 from Sanger sequencing) were compared to the 
average expression of mutations in the dominant (Dom) BMPC and MM clones.  (B) Characterization of the nucleotide substitutions 
exhibited by the putative MM subclonesOncotarget 2012; 3:  502-513 510 www.impactjournals.com/oncotarget
was observed after multiple samplings and correcting for 
Taq errors [16, 27]. Thus, it is possible that some of the 
subclones described in our study are genuine. Support for 
this possibility is provided by considering the error rate of 
the Taq polymerase (2 x 10-5) used in our study in context 
with our sequencing depth of nearly 30,000 reads at an 
average read length of 350-bases per sample. Thus, we 
calculated that the first PCR error could happen between 
cycles 21 and 22, which would result in multiple false 
positive clones with the largest clone size of 128 reads. 
However, the largest observed clone size in our data was 
56 indicating that the earliest possible PCR error cycle 
is 24. Based on this observation and that we required a 
minimal clone-size of 10 eliminating false positive clones 
from late-cycle PCR errors, we calculated that we would 
expect 7 false positive clones. With n=48 clones, the 
false positive rate in our data is estimated to be ~15%. 
Taken together with the observed bias for A-G or T-C 
substitutions in the subclones, we cautiously conclude 
that some of the clonally related sequences likely reflect 
genuine subclones. Further work using high fidelity Taq 
polymerase and serial samples obtained over time from 
MM patients is required to distinguish between these 
two possibilities. The latter approach would permit an 
assessment of whether the point mutations accumulated 
over time are a result of disease progression.
While numerous studies analyzing the repertoire 
and intraclonal heterogeneity in T and B cells using in-
depth sequencing have been published, to our knowledge, 
massively parallel pyrosequencing has not yet been used 
to analyze IGHV sequences expressed by either normal 
or malignant BM resident PCs. Instead, the emphasis has 
been on high throughput screening of natural or synthetic 
antibody repertoires [34, 48, 49]. While our analysis 
was limited to one normal BMPC sample and one MM 
sample, it is apparent that only with massively parallel 
sequencing and meticulous analysis will evidence of 
MM intraclonal heterogeneity be discovered. Our study 
importantly describes in detail the utility and potential 
pitfalls of using this approach to study IGHV clonal 
diversity in MM patients and in normal BMPCs. Finally, 
we also demonstrate the importance of using genomic 
DNA as the starting material and we underscore the need 
for cautious interpretation of IGHV sequence data using 
this approach. Despite the noted caveats, this methodology 
holds great promise for estimating the level of B lineage 
clonal diversity in healthy adults during the aging process 
as well as in estimating the diversity of normal B lineage 
cells in patients with B lineage malignancies.
METHODS AND MATERIALS
Ethics Statement
Mayo Clinic Institutional Review Board (IRB) 
approval was obtained for collection of bone marrow 
from a MM patient and a normal donor. Patients provided 
written informed consent to collect tissue and investigation 
was conducted in accordance with the ethical standards of 
the Declaration of Helsinki. 
A BM specimen was collected from the iliac crest of 
a 59 year old male with a confirmed diagnosis of untreated 
IgG lambda MM. At the time of collection, the patient had 
40% PCs in the marrow with a plasma cell labeling index 
of 3.0% and an M-spike of 3.5 g/dl upon immunofixation. 
Fluorescence in situ hybridization revealed a variety of 
abnormalities, i.e., +3, +9, t(4;14), -17p, and -13. 
Normal BM was collected from a 69 year old female 
undergoing orthopedic surgery for spinal stenosis. There 
was no history of hematologic malignancy or any other 
malignancy. 
Cell isolation
BM mononuclear cells obtained from both donors 
were isolated by Ficoll-Paque (GE Healthcare) density 
centrifugation. PCs were enriched by magnetic bead 
sorting using the Human CD138 Positive Selection kit 
(StemCell Technologies) with the Robosep instrument 
(StemCell Technologies) following the manufacturer’s 
protocol. The purity of both PC samples was >98% as 
assessed by morphology (Figure S2).
RNA and DNA isolation, cDNA synthesis, IGHV 
PCR, and sequence analysis
RNA was isolated by the TRIzol method (Invitrogen) 
and 2 µg of RNA was converted to cDNA using the GE 
Healthcare First Strand Synthesis kit. Genomic DNA was 
also isolated from PCs using the 5’ Prime ArchivePure 
DNA  Purification  Kit  (Fisher  Scientific).  Genomic 
DNA (200 ng) and cDNA (2 µl) were amplified using 
the Qiagen HotStarTaq MasterMix kit (Qiagen,) with Q 
solution (Qiagen) in a multiplex PCR reaction using 0.5 
µM of each of 7 sense primers representing the 7 IGHV 
families [13, 50] in conjunction with 0.5 µM of antisense 
primer to the IGHJ region capable of amplifying all 
IGHJ genes. All primers had appropriate modifications 
for downstream emulsion PCR, amplicon capture and 
pyrosequencing (Table S4). Amplification was carried out 
in a Perkin Elmer 9600 thermocycler (Perkin Elmer) using 
the following conditions optimized for comprehensive 
amplification: 95°C for 15 min; 30 cycles of 95°C for Oncotarget 2012; 3:  502-513 511 www.impactjournals.com/oncotarget
30 s, 60°C for 60 s, 72°C for 60 s; and a final cycle of 
72°C for 10 min. Amplified products were visualized on 
a 1.5% agarose TAE gel, excised and purified with the 
Purelink Gel Extraction kit (Invitrogen). Purified MM 
BMPC products were directly sequenced on an ABI 
PRISM 3730xl DNA Analyzer (Applied Biosystems/Life 
Technologies). All MM and normal BMPC PCR products 
were subcloned (Topo-TA Cloning Kit, Invitrogen) with at 
least 48 clones from each sample analyzed to ensure that 
our PCR strategy could amplify IGHV genes from all 7 
families. Resulting sequences were aligned to GL IGHV 
sequences using ImMunoGeneTics Information System 
reference sets and IMGT/V-Quest software (http://imgt.
cines.fr) [51].
Pyrosequencing and sequence analysis 
Purified  PCR  products  were  processed  for 
sequencing on a Roche 454 GS-FLX using the Titanium 
amplicon sequencing chemistry as described in the 
manufacturer’s protocol (Roche, 454 Life Sciences). The 
samples were run using 4 regions of an 8 region gasket 
and sequences were read from both the “A” and “B” 
primer ends.
Sequences that were shorter than the length 
distribution mode for each sample were filtered out and 
the remaining reads were aligned to GL IGHV sequences 
using IMGT/V-Quest software disallowing for insertions 
and deletions (indels) [51]. Non-Ig sequences or Ig 
sequences that were non-productive or did not have a 
complete HCDR3 were removed from the dataset.
After IGHV gene categorization and HCDR3 
analysis, we used a customized in-house method similar 
to that used by Chen et al [37] to further interrogate 
the  sequence  data.  Sequences  were  first  grouped  by 
IGHV gene categories and then by HCDR3 amino acid 
sequences. Those sequences with identical HCDR3s were 
further classified into subgroups with identical nucleotide 
sequence in the IGHV region. 
To validate possible MM subclones resulting from 
intraclonal heterogeneity we followed an algorithm 
similar to that described by Campbell et al [31] to 
eliminate sequence artifacts caused by inherent errors in 
pyrosequencing. Clone size was defined as all sequences 
with an identical HCDR3 amino acid sequence and the 
same IGHV gene. Given the potential for extraordinary 
sequence diversity of IGHV genes and our analysis of 
only 24,000-36,000 IGHV sequences (see Table S1), 
it should be noted that ‘clone size’ in our studies is still 
an approximation. From this cohort, sequences with 
apparent insertions or deletions of the same nucleotide 
within homopolymers (defined as tracts of 4 or more of 
the same nucleotide) or substitutions of nucleotides within 
2 base pairs of homopolymers were excluded from further 
analysis since these are more likely to be sequencing errors 
[52]. Of the remaining sequences, to be characterized as a 
MM-related subclone, we required the presence of 10 or 
more identical sequences in both the genomic DNA and 
cDNA-derived material, and both the forward and reverse 
orientations represented. Furthermore we required that 
all nucleotides within the sequence (including nucleotide 
changes in the subclones) had a Phred quality score greater 
than 20. 
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